KYMR
Kymera Therapeutics, Inc.
Latest Form 4:Sale$6.0MbyMainolfi Nello (Chief Executive Officer) · filed Jul 8, 2026
Kymera Therapeutics, Inc. (KYMR) has 57 SEC Form 4 filings (335 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Jul 27, 2026.
The most active filer is Director Booth Bruce with 15 filings. Insiders have net sold $428.7M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Nello Mainolfi
- Employees:208
- HQ:Watertown, MA, US
- IPO:2020-08-21
Insider Buying
$172.5M
reported purchases (SEC code P)
Insider Selling
$480.5M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$9.8B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 50,000 | $6.0M | Jul 8 | SEC ↗ | |
Jacobs Bruce N.First in 4 months | Chief Financial Officer | Sale | 77,109 | $8.9M | Jul 2 | SEC ↗ |
| Chief Business Officer | Sale | 3,389 | $387K | Jul 2 | SEC ↗ | |
| Chief Executive Officer | Sale | 80,000 | $9.2M | Jul 2 | SEC ↗ | |
| Director | Sale | 153,300 | $16.6M | Jul 2 | SEC ↗ | |
| Director | Sale | 467,878 | $51.6M | Jun 30 | SEC ↗ | |
| See Remarks and Footnotes | Sale | 1,630,658 | $173.7M | Jun 26 | SEC ↗ | |
| Director | Sale | 548,321 | $65.1M | Jun 26 | SEC ↗ | |
| Director | Sale | 1,408 | $141K | Jun 26 | SEC ↗ | |
| Director | Sale | 134,720 | $13.5M | Jun 26 | SEC ↗ | |
| Chief Business Officer | Sale | 5,000 | $570K | Jun 25 | SEC ↗ | |
| Director | Sale | 278,128 | $27.6M | Jun 23 | SEC ↗ | |
| Director | Sale | 116,812 | $10.6M | Jun 23 | SEC ↗ | |
| Director | Sale | 115,056 | $10.5M | Jun 23 | SEC ↗ | |
| Chief Business Officer | Sale | 2,500 | $248K | Jun 22 | SEC ↗ | |
| Chief Operating Officer | Sale | 12,905 | $1.0M | May 27 | SEC ↗ | |
| Chief Operating Officer | Sale | 4,279 | $349K | May 27 | SEC ↗ | |
| Director | Sale | 3,000 | $261K | May 11 | SEC ↗ | |
| Chief Executive Officer | Sale | 30,000 | $2.4M | Apr 29 | SEC ↗ | |
| Director | Sale | 6,000 | $540K | Apr 24 | SEC ↗ | |
| Chief Operating Officer | Sale | 300 | $27K | Apr 24 | SEC ↗ | |
| Director | Sale | 4,159 | $374K | Apr 16 | SEC ↗ | |
| Director | Sale | 5,335 | $480K | Apr 16 | SEC ↗ | |
| Chief Operating Officer | Sale | 5,251 | $473K | Apr 16 | SEC ↗ | |
| Chief Operating Officer | Sale | 1,300 | $117K | Apr 16 | SEC ↗ | |
| Chief Business Officer | Sale | 1,347 | $121K | Apr 16 | SEC ↗ | |
Goodman NoahFirst filing | Chief Business Officer | Sale | 8,264 | $723K | Apr 10 | SEC ↗ |
Goodman NoahFirst filing | Chief Business Officer | Sale | 2,000 | $175K | Apr 10 | SEC ↗ |
Ridloff ElenaFirst in 7 months | Director | Sale | 7,400 | $632K | Apr 1 | SEC ↗ |
Ridloff ElenaFirst in 7 months | Director | Sale | 4,600 | $393K | Apr 1 | SEC ↗ |
| Chief Operating Officer | Sale | 7,600 | $649K | Apr 1 | SEC ↗ | |
| Chief Operating Officer | Sale | 14,640 | $1.3M | Apr 1 | SEC ↗ | |
| Chief Operating Officer | Sale | 91,250 | $7.1M | Mar 25 | SEC ↗ | |
| Chief Operating Officer | Sale | 24,727 | $2.0M | Mar 25 | SEC ↗ | |
| Director | Sale | 2,500 | $198K | Mar 20 | SEC ↗ | |
| Chief Operating Officer | Sale | 25,758 | $2.1M | Mar 11 | SEC ↗ | |
Jacobs Bruce N.First in 6 months | Chief Financial Officer | Sale | 7,576 | $674K | Mar 4 | SEC ↗ |
Jacobs Bruce N.First in 6 months | Chief Financial Officer | Sale | 4,895 | $418K | Mar 4 | SEC ↗ |
| Chief Medical Officer | Sale | 5,613 | $499K | Mar 4 | SEC ↗ | |
| Chief Medical Officer | Sale | 4,895 | $418K | Mar 4 | SEC ↗ | |
Chadwick Jeremy GFirst filing | Chief Operating Officer | Sale | 2,039 | $181K | Mar 4 | SEC ↗ |
Chadwick Jeremy GFirst filing | Chief Operating Officer | Sale | 3,919 | $334K | Mar 4 | SEC ↗ |
| Director | Sale | 81,866 | $7.4M | Mar 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 30,000 | $2.7M | Feb 25 | SEC ↗ | |
| Director | Sale | 2,500 | $218K | Feb 20 | SEC ↗ | |
| Director | Sale | 5,500 | $374K | Jan 20 | SEC ↗ | |
| Chief Executive Officer | Sale | 30,000 | $2.3M | Dec 31 | SEC ↗ | |
Esposito PamelaFirst filing | Director | Sale | 27,563 | $2.3M | Dec 17 | SEC ↗ |
| Insider | Sale | 229,809 | $21.1M | Dec 12 | SEC ↗ | |
| Insider | Sale | 6,101 | $557K | Dec 12 | SEC ↗ | |
| Insider | Sale | 678 | $62K | Dec 12 | SEC ↗ | |
| Director, 10% Owner | Purchase | 2,005,813 | $172.5M | Dec 11 | SEC ↗ | |
| Chief Medical Officer | Sale | 49,307 | $4.4M | Dec 8 | SEC ↗ | |
| Director | Sale | 5,000 | $449K | Dec 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 100,000 | $8.9M | Dec 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 30,000 | $1.8M | Oct 29 | SEC ↗ | |
| Chief Medical Officer | Sale | 59,576 | $3.7M | Oct 15 | SEC ↗ | |
Gollob JaredFirst filing | Chief Medical Officer | Sale | 3,114 | $187K | Oct 14 | SEC ↗ |
Albers Jeffrey W.First filing | Director | Sale | 5,000 | $296K | Oct 14 | SEC ↗ |
Jacobs Bruce N.First filing | Chief Financial Officer | Sale | 79,220 | $4.0M | Sep 17 | SEC ↗ |
Mainolfi NelloFirst filing | Chief Executive Officer | Sale | 30,000 | $1.5M | Sep 16 | SEC ↗ |
Related companies
Kymera Therapeutics, Inc. is in the Healthcare sector.